Michael C Kaufman

US Patent:

7723536, May 25, 2010

Filed:

Feb 28, 2008

Appl. No.:

12/072730

Inventors:

Thomas J. Beauchamp - Fishers IN, US
Matthew J. LaMarche - Reading MA, US
Yuping Qiu - Princeton Junction NJ, US
Michael D. Kaufman - Lawrence KS, US
Hirokazu Arimoto - Nagoya, JP
David R. Jones - Milford OH, US
Kaoru Kobayashi - Osaka, JP

Assignee:

The Trustees Of The University of Pennsylvania - Philadelphia PA

International Classification:

C07F 9/02
C07F 9/28

US Classification:

556404, 568 9, 568 16

Abstract:

Synthetic methods and intermediates useful in the preparation of lactone containing compounds such as discodermolide and compounds which mimic the chemical or biological activity of discodermolide are provided.

US Patent:

7790756, Sep 7, 2010

Filed:

Oct 10, 2007

Appl. No.:

11/870388

Inventors:

Daniel L. Flynn - Lawrence KS, US
Peter A Petillo - Lawrence KS, US
Michael D Kaufman - Lawrence KS, US

Assignee:

Deciphera Pharmaceuticals, LLC - Lawrence KS

International Classification:

A61K 31/44

US Classification:

514341, 546143, 546162, 5462681, 5483751

Abstract:

The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.

US Patent:

7897762, Mar 1, 2011

Filed:

Sep 12, 2007

Appl. No.:

11/854293

Inventors:

Daniel L. Flynn - Lawrence KS, US
Peter A. Petillo - Lawrence KS, US
Michael D. Kaufman - Lawrence KS, US
William C. Patt - Lawrence KS, US

Assignee:

Deciphera Pharmaceuticals, LLC - Lawrence KS

International Classification:

A61K 31/519
C07D 487/04

US Classification:

544256, 5142621

Abstract:

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

US Patent:

8143293, Mar 27, 2012

Filed:

Apr 18, 2008

Appl. No.:

12/105408

Inventors:

Daniel L. Flynn - Lawrence KS, US
Peter A. Petillo - Lawrence KS, US
Michael D. Kaufman - Lawrence KS, US

Assignee:

Deciphera Pharmaceuticals, LLC - Lawrence KS

International Classification:

A61K 31/44
C07D 417/00
C07D 401/00

US Classification:

514341, 5462711, 546256, 5462784, 5462787

Abstract:

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocyclosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

US Patent:

8188113, May 29, 2012

Filed:

Sep 12, 2007

Appl. No.:

11/854354

Inventors:

Daniel L. Flynn - Lawrence KS, US
Peter A. Petillo - Lawrence KS, US
Michael D. Kaufman - Lawrence KS, US
William C. Patt - Lawrence KS, US

Assignee:

Deciphera Pharmaceuticals, Inc. - Lawrence KS

International Classification:

C07D 471/04
A61K 31/4375
A61P 35/00
A61P 29/00
A61P 19/00
A61P 11/00
A61P 9/00
A61P 37/00

US Classification:

514300, 546122

Abstract:

The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

US Patent:

8278331, Oct 2, 2012

Filed:

Oct 29, 2009

Appl. No.:

12/608578

Inventors:

Daniel L. Flynn - Lawrence KS, US
Peter A. Petillo - Lawrence KS, US
Michael D. Kaufman - Lawrence KS, US

Assignee:

Deciphera Pharmaceuticals, LLC - Lawrence KS

International Classification:

A61K 31/44

US Classification:

514333, 514269, 514274, 5462681, 544298

Abstract:

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

US Patent:

8461179, Jun 11, 2013

Filed:

Jun 7, 2012

Appl. No.:

13/491394

Inventors:

Daniel L. Flynn - Lawrence KS, US
Michael D. Kaufman - Lawrence KS, US
Peter A. Petillo - Lawrence KS, US

Assignee:

Deciphera Pharmaceuticals, LLC - Lawrence KS

International Classification:

A01N 43/42
A61K 31/44

US Classification:

514300, 546122

Abstract:

The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.

US Patent:

8486951, Jul 16, 2013

Filed:

Aug 21, 2012

Appl. No.:

13/590955

Inventors:

Daniel L. Flynn - Lawrence KS, US
Peter A. Petillo - Lawrence KS, US
Michael D. Kaufman - Lawrence KS, US

Assignee:

Deciphera Pharmaceuticals, LLC - Lawrence KS

International Classification:

A01N 43/54
C07D 239/42
C07D 401/04

US Classification:

514256, 514275, 514336, 514341, 544318, 544319, 5462721, 5462741, 5462751, 5462754

Abstract:

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilia syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.